U.S. Markets closed

VIVUS, Inc. (VVUS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.13+0.01 (+0.89%)
At close: 4:00PM EDT
People also watch
OREXARNAKERXAMRNXOMA

VIVUS, Inc.

900 East Hamilton Avenue
Suite 550
Campbell, CA 95008
United States
650-934-5200
http://www.vivus.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees65

Key Executives

NameTitlePayExercisedAge
Mr. Seth H. Z. FischerChief Exec. Officer and Director1.24MN/A61
Mr. Mark K. Oki CPAChief Financial Officer and Chief Accounting Officer480kN/A48
Mr. John L. Slebir Esq.Sr. VP of Bus. Devel., Gen. Counsel and Sec.667.16kN/A52
Dr. Santosh T. Varghese M.D.Chief Medical Officer564.94kN/A47
Mr. Richard FanteSr. AdvisorN/AN/A52
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Corporate Governance

VIVUS, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.